Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Review, H1 2018

  • ID: 4576060
  • Report
  • 64 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Advaxis Inc
  • Bavarian Nordic A/S
  • Inspyr Therapeutics Inc
  • NantKwest Inc
  • MORE
Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Review, H1 2018

Summary:

According to the recently published report 'Prostate Specific Antigen - Pipeline Review, H1 2018'; Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) pipeline Target constitutes close to 12 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes.

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Prostate-specific antigen (PSA) is a glycoprotein enzyme encoded by the KLK3 gene. PSA is secreted by the epithelial cells of the prostate gland. It is hydrolyzes semenogelin-1 this leads to the liquefaction of the seminal coagulum.

The report 'Prostate Specific Antigen - Pipeline Review, H1 2018' outlays comprehensive information on the Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 2, 1 and 4 respectively.

Similarly, the universities portfolio in Phase II stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology which include indications Prostate Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hormone Refractory (Castration Resistant and Androgen-Independent) Prostate Cancer.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77)
  • The report reviews Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Advaxis Inc
  • Bavarian Nordic A/S
  • Inspyr Therapeutics Inc
  • NantKwest Inc
  • MORE
Introduction

Report Coverage

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Overview

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Companies Involved in Therapeutics Development

Advaxis Inc

Bavarian Nordic A/S

Inovio Pharmaceuticals Inc

Inspyr Therapeutics Inc

NantKwest Inc

OncBioMune Pharmaceuticals Inc

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Drug Profiles

ADXS-PSA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target PSA for Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target PSA, PAP, Survivin and hTERT for Metastatic Hormone Refractory Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-114 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-115 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-5150 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody 1 to Inhibit PSA for Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonl Antibody to Inhibit PSA for Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Prostatac - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rilimogene galvacirepvec - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Castration Resistant Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Prostate Specific Antigen for Metastatic Hormone Refractory Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Dormant Products

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Discontinued Products

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Product Development Milestones

Featured News & Press Releases

Jun 01, 2018: Data Highlighting Advaxis’ ADXS-PSA Presented at ASCO Annual Meeting

May 17, 2018: Inovio Pharmaceuticals Demonstrates PSA Stabilizing Effect of INO-5150 Immunotherapy in Phase 1b Study for Prostate Cancer

Apr 02, 2018: Data Highlighting Advaxis ADXS-PSA Accepted as Poster Presentation at the American Society of Clinical Oncology Annual Meeting

Mar 28, 2018: OncBioMune Returns Protocol to Scientific Review Committee Overseeing Phase 2 Prostate Cancer Clinical Trial

Mar 22, 2018: Scientific Review Committee Meets on OncBioMune’s Phase 2 Prostate Cancer Clinical Trial

Mar 08, 2018: OncBioMune Selects Theradex as CRO for Two Phase 2 Trials of ProscaVax for Prostate Cancer

Feb 28, 2018: OncBioMune Submits Phase 2 Protocol to Urology Centers of North Texas

Feb 26, 2018: OncBioMune Provides Updates on two Phase 2 Clinical Trials of ProscaVax for Prostate Cancer

Feb 16, 2018: OncBioMune Provides Update on Market Activity

Feb 05, 2018: OncBioMune Signs Letter of Intent to Initiate Phase 2 Trial of ProscaVax for Advanced Prostate Cancer with Urology Clinics of North Texas

Jan 10, 2018: 70% of Advanced Prostate Cancer Patients Treated with ProscaVax Demonstrate Improvement in PSA Doubling Time

Dec 21, 2017: One-Year Follow-Up Shows 71.4% Progression-Free Survival in 14 Prostate Cancer Patients Treated with ProscaVax in Phase 1 Clinical Trial

Dec 05, 2017: 100% of Prostate Cancer Patients Completing 31-Week Post-Therapy Exam After Treatment with OncBioMune Immunotherapy Show No Disease Progression

Nov 13, 2017: 80% of Prostate Cancer Patients in OncBioMune Phase 1 Clinical Trial of ProscaVax Show No Disease Progression at the First Post-Therapy Follow-up

Sep 19, 2017: Two Abstracts Featuring Advaxis’ Lm-based Candidates Selected for Presentation at the 32nd Annual Society for Immunotherapy Cancer Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Advaxis Inc, H1 2018

Pipeline by Bavarian Nordic A/S, H1 2018

Pipeline by Inovio Pharmaceuticals Inc, H1 2018

Pipeline by Inspyr Therapeutics Inc, H1 2018

Pipeline by NantKwest Inc, H1 2018

Pipeline by OncBioMune Pharmaceuticals Inc, H1 2018

Dormant Projects, H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Advaxis Inc
  • Bavarian Nordic A/S
  • Inovio Pharmaceuticals Inc
  • Inspyr Therapeutics Inc
  • NantKwest Inc
  • OncBioMune Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll